| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | 0 |
Sells | $237,380 | 6 | 100 |
| Maltbie Shane | Chief Financial Officer | 0 | $0 | 2 | $15,117 | $-15,117 |
| HERSHBERG ROBERT | See Remarks | 0 | $0 | 2 | $48,661 | $-48,661 |
| Kohli Aditya | director | 0 | $0 | 2 | $173,602 | $-173,602 |
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Over the last 12 months, insiders at HilleVax, Inc. have bought $0 and sold $237,380 worth of HilleVax, Inc. stock.
On average, over the past 5 years, insiders at HilleVax, Inc. have bought $15.07M and sold $493.99M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 8,850 shares for transaction amount of $128,325 was made by Frazier Life Sciences X, L.P. (10 percent owner) on 2024‑04‑04.
| 2025-02-11 | Sale | HERSHBERG ROBERT | See Remarks | 11,901 0.0232% | $1.76 | $21,003 | +3.45% | |
| 2025-02-11 | Sale | Maltbie Shane | Chief Financial Officer | 4,345 0.0084% | $1.76 | $7,659 | +3.45% | |
| 2025-02-04 | Sale | HERSHBERG ROBERT | See Remarks | 14,634 0.0291% | $1.89 | $27,658 | -5.76% | |
| 2025-02-04 | Sale | Maltbie Shane | Chief Financial Officer | 3,946 0.0078% | $1.89 | $7,458 | -5.76% | |
| 2024-05-22 | Sale | Kohli Aditya | director | 6,000 0.0126% | $14.73 | $88,372 | -86.85% | |
| 2024-05-21 | Sale | Kohli Aditya | director | 6,000 0.0118% | $14.21 | $85,230 | -87.20% | |
| 2024-05-20 | Sale | Kohli Aditya | director | 6,000 0.0129% | $15.45 | $92,689 | -87.16% | |
| 2024-05-03 | Sale | Kohli Aditya | director | 723 0.0015% | $14.15 | $10,233 | -86.33% | |
| 2024-05-02 | Sale | Kohli Aditya | director | 6,000 0.0121% | $14.01 | $84,081 | -86.70% | |
| 2024-05-01 | Sale | Kohli Aditya | director | 175 0.0004% | $14.03 | $2,456 | -86.25% | |
| 2024-04-05 | Sale | Kohli Aditya | director | 6,000 0.012% | $14.44 | $86,640 | -87.02% | |
| 2024-04-04 | Sale | Kohli Aditya | director | 6,000 0.0122% | $14.71 | $88,245 | -86.97% | |
| 2024-04-04 | Frazier Life Sciences X, L.P. | 10 percent owner | 8,850 0.0178% | $14.50 | $128,325 | -86.97% | ||
| 2024-04-03 | Sale | Kohli Aditya | director | 6,000 0.0122% | $14.93 | $89,582 | -87.25% | |
| 2024-03-28 | McLoughlin Sean | Chief Operating Officer | 1,250 0.0026% | $16.98 | $21,225 | -88.64% | ||
| 2024-03-20 | Sale | Kohli Aditya | director | 6,000 – | $164,221.00 | $985.33M | -88.21% | |
| 2024-03-19 | Sale | Kohli Aditya | director | 6,000 0.0126% | $17.42 | $104,492 | -89.10% | |
| 2024-03-18 | Sale | Kohli Aditya | director | 6,000 0.0129% | $17.66 | $105,937 | -89.02% | |
| 2024-03-08 | Sale | Kohli Aditya | director | 6,000 0.0128% | $18.66 | $111,959 | -89.63% | |
| 2024-03-07 | Sale | Kohli Aditya | director | 6,000 0.0124% | $18.37 | $110,213 | -89.75% |
| HERSHBERG ROBERT | See Remarks | 1101498 2.1968% | $2.09M | 0 | 3 | |
| Kohli Aditya | director | 764878 1.5255% | $1.45M | 0 | 19 | |
| Maltbie Shane | Chief Financial Officer | 79887 0.1593% | $151,785.30 | 0 | 3 | |
| Frazier Life Sciences X, L.P. | 10 percent owner | 8544187 17.0403% | $16.23M | 1 | 0 | <0.0001% |
| Heron Patrick J | 8535337 17.0226% | $16.22M | 1 | 0 | <0.0001% | |
| Borkowski Astrid | Chief Medical Officer | 161260 0.3216% | $306,394.00 | 0 | 6 | |
| McLoughlin Sean | Chief Operating Officer | 1250 0.0025% | $2,375.00 | 1 | 0 | <0.0001% |
$30,470,407 | 140 | 20.39% | $99.03M | |
$49,091,668 | 110 | 13.11% | $90.67M | |
$16,245,616 | 40 | 123.58% | $104.37M | |
$140,938,207 | 36 | 14.75% | $100.35M | |
$53,912,175 | 35 | -8.02% | $87.8M | |
$64,487,106 | 32 | -22.92% | $98.98M | |
$36,079,815 | 31 | 43.23% | $88.15M | |
$40,617,659 | 23 | 2.15% | $94M | |
$1,239,833 | 16 | 53.23% | $103.79M | |
$13,043,783 | 8 | 732.82% | $91.08M | |
$299,343 | 6 | -44.75% | $94.4M | |
$556,839 | 5 | 13.42% | $96.57M | |
$16,003,671 | 3 | 55.38% | $89.6M | |
HilleVax, Inc. (HLVX) | $30,149,552 | 3 | -66.74% | $95.27M |
$9,999,990 | 2 | 25.53% | $101.58M | |
$63,731 | 1 | -19.50% | $98.77M | |
$3,620 | 1 | 94.16% | $94.83M | |
$1,250 | 1 | 278.21% | $93.96M | |
$20,020,000 | 1 | -75.24% | $95.51M |
| Increased Positions | 31 | +34.07% | 802,433 | +2.21% |
| Decreased Positions | 36 | -39.56% | 1M | -3.85% |
| New Positions | 12 | New | 482,873 | New |
| Sold Out Positions | 7 | Sold Out | 288,928 | Sold Out |
| Total Postitions | 86 | -5.49% | 36M | -1.64% |
| Frazier Life Sciences Management, L.P. | $20,809.00 | 21.23% | 10.62M | 0 | 0% | 2024-12-31 |
| Tang Capital Management Llc | $9,643.00 | 9.84% | 4.92M | 0 | 0% | 2024-12-31 |
| Lightspeed Management Company, L.L.C. | $4,589.00 | 4.68% | 2.34M | +2M | New | 2024-12-31 |
| Blackrock, Inc. | $4,107.00 | 4.19% | 2.1M | -67,775 | -3.13% | 2025-03-31 |
| Franklin Resources Inc | $3,837.00 | 3.92% | 1.96M | 0 | 0% | 2024-12-31 |
| Deerfield Management Company, L.P. (Series C) | $3,690.00 | 3.77% | 1.88M | 0 | 0% | 2024-12-31 |
| Carlyle Group Inc. | $3,603.00 | 3.68% | 1.84M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $3,148.00 | 3.21% | 1.61M | +32,789 | +2.08% | 2024-12-31 |
| Balyasny Asset Management L.P. | $1,965.00 | 2.01% | 1M | -12,057 | -1.19% | 2024-12-31 |
| Stepstone Group Lp | $1,620.00 | 1.65% | 826,569 | 0 | 0% | 2024-12-31 |